← Back to all trials
Not Yet Recruiting
NCT07579910
Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
Conditions: MPS IIIB
Sex: All
Ages: 1 Year – 5 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 14
Sponsor: Spruce Biosciences
Summary
The primary objectives of this study are to evaluate the effects of Tralesinidase Alfa (TA) on cognition
Eligibility Criteria
Inclusion Criteria:
Has a diagnosis of MPS IIIB confirmed by deficient NAGLU enzyme activity during screening.
Has nonattenuated severe MPS IIIB by the Genotype and Clinical Assessment Committee.
Is ≥1 and ≤5 years of age with BSID-III-C raw score of \
Source: ClinicalTrials.gov (NCT07579910). StuddyBuddy aggregates publicly available trial information.
